There are currently 53 ongoing clinical trials involving Cataract
Of the 53 trials,22 trials are in Phase IV
Furthermore, 15 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Cataract, anophthalmology indication.The largest number of ongoing clinical trials for Cataract is conducted in the Asia-Pacific region. North Americaand Europe are among some of the other prominent regions involved in Cataract-related drug trials.
Isfahan University of Medical Sciences: The leading ongoing Cataract related clinical trial sponsor
Isfahan University of Medical Sciencesis the top sponsor for Cataract-related ongoing clinical trials.
University of Helsinki, Dar El Oyoun Hospital, and University Hospitals Leuvenare a few other notable clinical trial sponsors involved in Cataract. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Cataract
Pirfenoxone (Kary Uni), Dexamethasone and Tobramycin (Tobadex), and Bendazac (Bendazac Lysine) are among the key marketed drugs involving Cataract.
Pirenoxine also referred to as pirfenoxone (Kary Uni) is a carboxylic acid derivative, acts as anti-cataract agent. It is formulated in the form of suspension drops for ophthalmic route of administration. It is indicated for the treatment of early senile cataract, and cataract. Pirenoxine inhibits lens opacification and therefore prevents cataract formation. It interacts with calcium and selenite ions, which play a central role in the formation of lens cataracts. This in turn can help stop crystals in the eye that are water soluble from insolubilization, which allows for the eye lens and vision to remain clear. Pirenoxine was first approved in 1990 and is marketed globally including Japan, South Korea, Indonesia, and China by several prominent pharma giants including Santen Pharmaceutical China Co Ltd, TaeJoon Pharmaceuticals Co Ltd, and PT Ferron Par Pharmaceuticals.
Dexamethasone and Tobramycin (Tobadex) is a fixed-dose combination, acts as an anti-infective and anti-inflammatory agent. It functions via 30S Ribosomal Subunit (30S RNA) Inhibitor; Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as drops-suspension for ophthalmic route of administration. Tobadex is marketed for the treatment of Cataract and several other indications including Fever, Bacterial Conjunctivitis, and Anterior Uveitis. Tobadex was first approved in 2017 and is marketed in South Korea by Kolmar Korea Co Ltd.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward